Company Reports

Recent Updates

All Reports

Company Report

Integral’s strategy centers on capitalizing on the growing demand for diagnostic imaging. Volume growth is driven by population growth, ageing demographics, higher incidence of diseases, and wider adoption of preventative diagnostics. These drivers are often greater in regional areas which Integral focuses on.
Company Report

Integral’s strategy centers on capitalizing on the growing demand for diagnostic imaging. Volume growth is driven by population growth, ageing demographics, higher incidence of diseases, and wider adoption of preventative diagnostics. These drivers are often greater in regional areas which Integral focuses on.
Stock Analyst Note

Integral's interim 2026 underlying revenue grew 7% while operating EBITDA margin rose a strong 130 basis points to 21% on a pro forma basis. They kept full-year operating EBITDA margin guidance of 21%, implying a slight second-half uplift on normal sales seasonality and as cost savings annualize.
Stock Analyst Note

Integral guided to fiscal 2026 EBITDA margins expanding to 21%, after lifting 150 basis points to 20% last year. This is driven by reiterated total annualized cost savings of AUD 14 million from the acquisition of Capitol Health, ramp up of new sites, and procurement efficiencies. Shares rose 5%.
Stock Analyst Note

Integral Diagnostics’ fiscal 2025 EBITDA grew 38% on the successful integration of Capitol Health in December. EBITDA margin on a pro forma basis is up 150 basis points to 20%, and the firm increased annual cost-saving targets by another AUD 4 million. Shares reacted positively, up 11%.
Company Report

Integral’s strategy centers on capitalizing on the growing demand for diagnostic imaging. Volume growth is driven by population growth, ageing demographics, higher incidence of diseases, and wider adoption of preventative diagnostics. These drivers are often greater in regional areas which Integral focuses on.
Stock Analyst Note

Medicare Australia statistics for benefits paid in core pathology and diagnostic imaging for the five months to May 2025 increased by 5% and 7%, respectively, on the previous corresponding period, key revenue drivers for Sonic Healthcare, Integral Diagnostics, and Australian Clinical Labs.
Stock Analyst Note

No-moat Integral Diagnostic’s interim fiscal 2025 underlying Australian revenue grew a respectable 8%, driven by 5% average fee growth on increases in government funding and continued favorable mix impact, but was below industry growth of 11%. Underlying group EBITDA also grew 8% to AUD 47 million, but the market was clearly disappointed about profitability.
Stock Analyst Note

No-moat Integral Diagnostic’s first-quarter fiscal 2025 group revenue grew 8.6% on the previous corresponding period. Australian revenue growth was slightly below market and our expectations. However, New Zealand's revenue growth was strong, and we leave our full-year organic group revenue growth forecast of 8.6% unchanged, albeit slightly different compositionally. Given a delay in regulatory approval, we now credit six months earnings contributions from Capitol Health in fiscal 2025 versus nine months previously. We maintain our AUD 3.40 fair value estimate, with shares appearing slightly undervalued.
Stock Analyst Note

No-moat Integral Diagnostics' fiscal 2024 Australian revenue grew 7.2%, driven by increases to government funding and out-of-pocket fees, but was below market growth of 9.5%. However, we maintain our AUD 3.60 fair value estimate, with shares undervalued. We remain positive on Integral's margin recovery as it focuses on digitization and higher-value imaging modalities. Teleradiology now accounts for roughly 15% of Integral's Australian revenue. Our long-term estimates, including a group midcycle fiscal 2034 EBITDA margin forecast of 24%, are broadly unchanged.
Stock Analyst Note

No-moat Integral Diagnostics and Capitol Health are seeking to merge. The firms have agreed to complete due diligence and finalize a binding agreement during four weeks of mutual exclusivity. The current proposal would see Capitol shareholders receive 0.12849 Integral shares per Capitol share, implying 63% ownership of the combined group for Integral shareholders and 37% for Capitol shareholders. This would add a significant 138 million shares, a 59% expansion of Integral’s current share count.
Stock Analyst Note

No-moat Integral’s first-half fiscal 2024 Australian revenue increased 7.8% on the previous corresponding period, driven by increases to government funding and out-of-pocket fees, but was below market growth of 9.5%. We trim our group revenue forecasts by 3% on average over the next 10 years, but this is largely offset by the time value of money and lower forecast expenditure. Our midcycle EBITDA margin forecast increases by 50 basis points to 25.8%, and we maintain our AUD 3.60 fair value estimate with shares remaining undervalued.
Stock Analyst Note

No-moat Integral’s first-quarter fiscal 2024 Australian revenue grew 8.4% on the previous corresponding period, or PCP, versus market growth of 9.5%. We slightly trim our group revenue forecasts by 2% on average over the next 10 years but this is largely offset by the time value of money and lower forecast capital expenditure and depreciation expense. Our EBIT forecasts are broadly unchanged, and we maintain our AUD 3.60 fair value estimate with shares remaining undervalued.

Sponsor Center